Physician profile
Katie E Murray
NPI 1104139781
$2,311.43
in general payments reported to CMS, 2019-2025
20 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $211 · 2022: $1,112 · 2023: $561 · 2024: $232 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $988.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $530.53 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $341.87 | 2022-2025 | Jardiance |
| Amgen INC. | $304.53 | 2021-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $242.12 | 2021-2023 | Lifevest |
| Abbott Laboratories | $201.57 | 2022-2023 | Cardiomems |
| Sanofi-Aventis U.S. LLC | $119.66 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $113.29 | 2022-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $100.44 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $79.35 | 2021-2023 | |
| Lemaitre Vascular, INC. | $42.84 | 2022 | |
| Baxter Healthcare | $41.45 | 2025 | Perclot |
| Amarin Pharma, INC. | $38.73 | 2022 | |
| Novo Nordisk INC | $38.60 | 2022-2023 | Ozempic |
| Alnylam Pharmaceuticals INC. | $37.82 | 2025 | Onpattro |
| Kiniksa Pharmaceuticals, LTD. | $17.47 | 2023 | Arcalyst |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $16.86 | 2024 | Arcalyst |
| Philips North America LLC | $15.54 | 2024 | (5091) Amb Mon & Diag Und |
| Actelion Pharmaceuticals US, INC. | $15.08 | 2021 | |
| Cvrx, INC. | $13.68 | 2024 | Barostim Neo System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.